0000950170-24-035517.txt : 20240322
0000950170-24-035517.hdr.sgml : 20240322
20240322174506
ACCESSION NUMBER: 0000950170-24-035517
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240320
FILED AS OF DATE: 20240322
DATE AS OF CHANGE: 20240322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KASINGER JAMES R.
CENTRAL INDEX KEY: 0001708172
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 24776427
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS, INC.
STREET 2: 610 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
ownership.xml
4
X0508
4
2024-03-20
0001674416
CRISPR Therapeutics AG
CRSP
0001708172
KASINGER JAMES R.
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
BOSTON
MA
02127
false
true
false
false
General Counsel and Secretary
false
Stock Option (Right to Buy)
72.94
2024-03-20
4
A
false
33333
0
A
2034-03-20
Common Shares
33333
33333
D
Restricted Stock Units
2024-03-20
4
A
false
25000
0
A
Common Shares
25000
25000
D
This option was granted on March 20, 2024 with respect to 33,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2024.
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.
/s/ AJ Silver, attorney-in-fact
2024-03-22